Q32 Bio Inc. (QTTB )

Currency in USD Disclaimer
$11.89 -$0.14 (-1.16%)
Closed 06/09/2026
$11.59
$12.55
$1.35
$13.19

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol QTTB
  • Company Q32 Bio Inc.
  • Price $11.89
  • Changes Percentage -1.16
  • Change -0.14
  • Day Low $11.59
  • Day High $12.55
  • Year High $13.19
  • Year Low $1.35
  • Market Cap $155,742,743
  • Price Avg 50 EMA (D) $6.53
  • Price Avg 200 EMA (D) $4.04
  • Exchange NASDAQ
  • Volume 535,048
  • Average Volume 712,040
  • Open $12.19
  • Previous Close $12.03
  • EPS 2.78
  • PE 4.38
  • Earnings Announcement 2026-08-05 04:00:00
  • Shares Outstanding $12,776,271

Company brief: Q32 BIO INC. (QTTB )

  • Healthcare
  • Biotechnology
  • Ms. Jodie Pope Morrison
  • N/A
  • 03-28-2018
  • US7469641051

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

QTTB Corporation News

Income Statement